The polymer, called polyethylene glycol or PEG, works by "fusing" the membranes of damaged nerve cells, and it can be applied up to eight hours after the injury without adversely affecting the patient ...

PEG-Naloxol (NKTR-118) in Phase II clinical trials. Clinical benefit has already been demonstrated with polymer–drug conjugates bearing classical chemotherapeutic agents. The future of cancer ...

the process of attaching strands of polyethylene glycol (PEG) polymer chains to the active drug molecules. The covalent attachment of PEG to a drug or therapeutic protein can help ‘mask’ it ...

Beyond Anticancer Therapeutics: Polymer–Drug Conjugates for the Treatment of Diseases other than Cancer In the last decade, the field of polymer–drug conjugates has expanded towards novel ...